Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc.

Track LCTX — free

Use LCTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.08 -0.02 (-1.82%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$273.14M
Shares
252.91M

LCTX metrics

62 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.08
Market cap
$273.14M

Price action

19 metrics
Price change (1W)
-2.7%
Price change (30D)
-4.4%
Price change (3M)
-9.2%
Price change (6M)
-41.6%
Price change (YTD)
-35.3%
Price change (1Y)
-10.0%
Trailing year
Price change (5Y)
-61.3%
52-week high
$1.96
52-week low
$1.03
Change from 52-week high
-44.9%
Change from 52-week low
+4.9%
Annualized volatility
56.1%
Beta
1.5
RSI (14D)
44.9
Price vs SMA 50
-6.0%
Price vs SMA 200
-26.3%
Avg volume (3M)
1.32M
Relative volume
0.4
Average dollar volume
$1.59M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
252.91M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
20.9×
reciprocal yield 4.8%
P / book
4.5
reciprocal yield 22.3%
FCF yield
-8.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-11.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-205.2%
Trailing 12 months
Net margin
-246.6%
Gross profit (TTM)
$8.27M
Operating profit (TTM)
−$26.85M
Net income (TTM)
−$32.26M
Trailing 12 months
Diluted EPS (TTM)
$-0.19
FCF margin
-186.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.80

Growth

11 metrics
Revenue growth YoY
-61.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$13.08M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.5%
Year over year · more shares
Revenue CAGR (3Y)
-0.3%
Revenue CAGR (5Y)
+51.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-53.0%
Return on assets
-30.4%
Debt / equity
—
Current ratio
6.6
EBITDA (TTM)
−$26.11M
Free cash flow (TTM)
−$24.39M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$50.83M
Latest balance sheet
Cash & equivalents
$37.35M
Total assets
$106.22M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$23.82M
Capital expenditures (TTM)
$574,000
R&D (TTM)
$20.52M
SG&A (TTM)
—
Stock compensation (TTM)
$5.07M
R&D / revenue
156.8%
Stock compensation / revenue
38.8%

Ownership (13F)

3 metrics
13F filers
131
13F filer change QoQ
0
Institutional ownership
46.1%

Short interest

3 metrics
Short interest
11.2%
Latest settlement · 35.1 days to cover
Days to cover
35.1d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 876343 CUSIP 53566P109 13F (30d) 79 filings 79 filers Visit website Investor relations